Alvotech (ALVO) announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly FDA approved high-concentration interchangeable biosimilar to Humira.
Alvotech (ALVO) announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly FDA approved high-concentration interchangeable biosimilar to Humira.
Alvotech (ALVO) announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly FDA approved high-concentration interchangeable biosimilar to Humira.
התרופה הזו היא ביומילר ל-Humira, מה שאומר שהיא דומה מאוד לתרופה קיימת אך מיוצרת על ידי חברה אחרת. היא גם אושרה על ידי ה-FDA. מניות Alvotech, שניתן למצוא עוד עליהן
The latest update is out from Teva Pharmaceutical (TEVA). Teva Pharmaceutical Industries Limited has announced a significant change in their financial reporting structure, aligning with their Pivot to Growth strategy.
Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA) announced that the FDA has approved SELARSDI, or ustekinumab-aekn, injection for subcutaneous use, as a biosimilar to